Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$58.87 USD
+0.64 (1.10%)
Updated Nov 22, 2024 04:00 PM ET
After-Market: $58.89 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Price, Consensus and EPS Surprise
BMY 58.87 +0.64(1.10%)
Will BMY be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for BMY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BMY
Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug
Is Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) a Strong ETF Right Now?
BMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Should Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) Be on Your Investing Radar?
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
Other News for BMY
Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC
Replimune climbs after updates on lead drug
Optimism over global healthcare sector rises: Jefferies
XLV: Healthcare Stocks In Critical Condition (Rating Downgrade)
Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)